Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances
Confirms Trial Weighted Towards Overall Survival Endpoint
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
